The new AUC for Bone Scintigraphy addresses several clinical scenarios for metastatic bone disease, across a variety of oncologic indications. To improve utilization and guide providers to use bone scan in a more appropriate way, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and the American Society of Clinical Oncology (ASCO) have collaboratively developed criteria for the appropriate use of this imaging technology to aid in the diagnosis of people with malignant diseases such as breast cancer and prostate cancer.
SNMMI assembled an autonomous Bone Scan Workgroup consisting of experts in the field of nuclear medicine including radiologists and oncologists to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the Bone Scan Workgroup put together, which they used to make their recommendations for clinical use.
To view the development process, please click the following link: SNMMI AUC Development Process.